South Rampart Pharma Announces Patient Enrollment and Dosing Underway in Phase 1 Study Evaluating Novel Non-Opioid Approach to Pain with Lead Program, SRP-3D (DA)

SRP-3D (DA) has demonstrated a compelling safety profile over currently available pain medicationsPotential to address the significant unmet need for new, safe, effective, and non-opioid pain medicationsDevelopment program funded by the National …